Compare WETH & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | MRKR |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 18.7M |
| IPO Year | 2020 | 2010 |
| Metric | WETH | MRKR |
|---|---|---|
| Price | $1.09 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 134.8K | 40.5K |
| Earning Date | 04-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.38 | ★ 33.61 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $45,136,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $936.27 |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.82 | $0.81 |
| 52 Week High | $3.68 | $2.46 |
| Indicator | WETH | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 35.81 |
| Support Level | $0.95 | $1.05 |
| Resistance Level | $1.49 | $1.54 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 29.18 | 22.15 |
Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).